Product Description
Raltegravir is the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor; it targets the strand transfer step of HIV-1 integration. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19231980/)
Mechanisms of Action: HIV Integrase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: HIV Infections
Phase 2: Biliary Cirrhosis|Cholangitis|Liver Cirrhosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT03174977 | P1 |
Recruiting |
HIV Infections |
2024-11-01 |
|
| DORAL | P2 |
Active, not recruiting |
HIV Infections |
2023-05-06 |
|
| Pro00082571 | P2 |
Completed |
Cholangitis|Biliary Cirrhosis|Liver Cirrhosis |
2022-10-01 |
|
| 2017-000986-60 | P3 |
Active, not recruiting |
HIV Infections |
2019-03-27 |